Quince Therapeutics, Inc.
QNCX
$1.52
-$0.13-7.88%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.79M | 1.78M | 3.63M | 4.70M | 4.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.93M | 7.61M | 8.55M | 8.84M | 8.67M |
| Operating Income | -12.93M | -7.61M | -8.55M | -8.84M | -8.67M |
| Income Before Tax | -14.98M | -12.45M | -5.48M | -27.69M | -11.12M |
| Income Tax Expenses | 47.00K | 7.00K | 13.00K | 36.00K | 31.00K |
| Earnings from Continuing Operations | -15.03M | -12.46M | -5.49M | -27.73M | -11.15M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.03M | -12.46M | -5.49M | -27.73M | -11.15M |
| EBIT | -12.93M | -7.61M | -8.55M | -8.84M | -8.67M |
| EBITDA | -12.90M | -7.59M | -8.46M | -8.80M | -8.63M |
| EPS Basic | -0.34 | -0.28 | -0.13 | -0.64 | -0.26 |
| Normalized Basic EPS | -0.18 | -0.11 | -0.11 | -0.12 | -0.12 |
| EPS Diluted | -0.34 | -0.28 | -0.13 | -0.64 | -0.26 |
| Normalized Diluted EPS | -0.18 | -0.11 | -0.11 | -0.12 | -0.12 |
| Average Basic Shares Outstanding | 43.94M | 43.78M | 43.16M | 43.10M | 43.01M |
| Average Diluted Shares Outstanding | 43.94M | 43.78M | 43.16M | 43.10M | 43.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |